188 related articles for article (PubMed ID: 26118884)
1. [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes].
Besse B
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S93-5. PubMed ID: 26118884
[TBL] [Abstract][Full Text] [Related]
2. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
3. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
Gadgeel SM
Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
[No Abstract] [Full Text] [Related]
4. [Targeted therapies in non-small cell lung cancer in 2014].
Leduc C; Besse B
Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
[TBL] [Abstract][Full Text] [Related]
5. Update on systemic therapy of advanced non-small-cell lung cancer.
Cufer T; Knez L
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
[TBL] [Abstract][Full Text] [Related]
6. ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.
Socinski MA
Oncology (Williston Park); 2011 Jun; 25(7):601, 604, 607. PubMed ID: 21888259
[No Abstract] [Full Text] [Related]
7. The future of NSCLC: molecular profiles guiding treatment decisions.
Tsao AS; Papadimitrakopoulou VA
Oncology (Williston Park); 2011 Jun; 25(7):607, 614. PubMed ID: 21888260
[No Abstract] [Full Text] [Related]
8. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
Iams WT; Lovly CM
Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
[TBL] [Abstract][Full Text] [Related]
9. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
10. Acquired resistance in oncogene-addicted non-small-cell lung cancer.
Sini C; Tuzi A; Rossi G; Russo A; Pezzuto A
Future Oncol; 2018 Jun; 14(13s):29-40. PubMed ID: 29989451
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Haddad FG; Kourie HR; Kattan J
Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
[No Abstract] [Full Text] [Related]
12. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
13. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
14. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
15. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
16. The cellular origins of drug resistance in cancer.
Oxnard GR
Nat Med; 2016 Mar; 22(3):232-4. PubMed ID: 26937615
[No Abstract] [Full Text] [Related]
17. [Molecular targeted therapies and cytotoxics: Friends or foes?].
Vignot S; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
[No Abstract] [Full Text] [Related]
18. Targeted therapy and new anticancer drugs in advanced disease.
Silva S; Danson S
Thorac Surg Clin; 2013 Aug; 23(3):411-9. PubMed ID: 23931023
[TBL] [Abstract][Full Text] [Related]
19. Oncogene addicted non-small-cell lung cancer: current standard and hot topics.
Vecchiarelli S; Bennati C
Future Oncol; 2018 Jun; 14(13s):3-17. PubMed ID: 29989448
[TBL] [Abstract][Full Text] [Related]
20. [Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].
Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):66-72. PubMed ID: 28103976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
